Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis

References

• MiloRKahanaEMultiple sclerosis: geoepidemiology, genetics and the environmentAutoimmun Rev201095A387A39419932200
   PubMed Web of Science ®Google Scholar
• CampbellJDGhushchyanVMcQueenRBBurden of multiple sclerosis on direct, indirect costs and quality of life: national US estimatesMult Scler Relat Disord20143222723625878010
   PubMed Web of Science ®Google Scholar
• GelfandJMMultiple sclerosis: diagnosis, differential diagnosis, and clinical presentationHandb Clin Neurol201412226929024507522
   PubMedGoogle Scholar
• TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
   PubMed Web of Science ®Google Scholar
• WingerchukDMWeinshenkerBGDisease modifying therapies for relapsing multiple sclerosisBMJ2014354i3518
   Google Scholar
• ScalfariANeuhausADaumerMMuraroPAEbersGCOnset of secondary progressive phase and long-term evolution of multiple sclerosisJ Neurol Neurosurg Psychiatry2013851677523486991
   PubMed Web of Science ®Google Scholar
• TremlettHZhaoYDevonshireVNatural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similaritiesJ Neurol2009256337438119308306
   PubMed Web of Science ®Google Scholar
• YermakovSDavisMCalnanMImpact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosisJ Med Econ201518971172025903661
   PubMed Web of Science ®Google Scholar
• RubinSMManagement of multiple sclerosis: an overviewDis Mon201359725326023786659
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• PelletierDHaflerDAFingolimod for multiple sclerosisN Engl J Med2012366433934722276823
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• TorkildsenOMyhrKMBoLDisease-modifying treatments for multiple sclerosis: a review of approved medicationsEur J Neurol201623Suppl 1182726563094
   PubMed Web of Science ®Google Scholar
• HartungDMBourdetteDNAhmedSMWhithamRHThe cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?Neurology201584212185219225911108
   PubMed Web of Science ®Google Scholar
• ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityBrain2010133Pt 71914192920534650
   PubMed Web of Science ®Google Scholar
• BrexPACiccarelliOO’RiordanJLSailerMThompsonAJMillerDHA longitudinal study of abnormalities on MRI and disability from multiple sclerosisN Engl J Med2002346315816411796849
   PubMed Web of Science ®Google Scholar
• GoodinDSTraboulseeAKnappertzVRelationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisJ Neurol Neurosurg Psychiatry201283328228722193561
   PubMed Web of Science ®Google Scholar
• AgashivalaNWuNAbouzaidSCompliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort studyBMC Neurol20131313824093542
   PubMed Web of Science ®Google Scholar
• BergvallNPetrillaAAKarkareSUPersistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysisJ Med Econ2014171069670725019581
   PubMedGoogle Scholar
• EvansCMarrieRAZhuFAdherence and persistence to drug therapies for multiple sclerosis: a population-based studyMult Scler Relat Disord20168788527456879
   PubMed Web of Science ®Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
   PubMed Web of Science ®Google Scholar
• MunsellMLocklearJCPhillipsALFreanMMenzinJAn assessment of adherence among multiple sclerosis patients newly initiating treatment with a self-injectable versus oral disease-modifying drugNeurology201584143281
   Google Scholar
• CohenBACoylePKLeistTOleen-BurkeyMASchwartzMZwibelHTherapy optimization in multiple sclerosis: a cohort study of therapy adherence and risk of relapseMult Scler Relat Disord201541758225787057
   PubMed Web of Science ®Google Scholar
• Oleen-BurkeyMDorACastelli-HaleyJLageMJThe relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetateJ Med Econ201114673974721913796
   PubMedGoogle Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2011181697720561039
   PubMed Web of Science ®Google Scholar
• SaizAMoraSBlancoJTherapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis: COMPLIANCE studyNeurologia201530421422224484756
   PubMed Web of Science ®Google Scholar
• McGregorJCKimPWPerencevichENUtility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organismsAm J Epidemiol2005161548349315718484
   PubMed Web of Science ®Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• NauDPProportion of days covered (PDC) as a preferred method of measuring medication adherence Available from: http://www.pqaal-liance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdfAccessed February 6, 2017
   Google Scholar
• ChastekBJOleen-BurkeyMLopez-BresnahanMVMedical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claimsJ Med Econ201013461862520883151
   PubMedGoogle Scholar
• LizanLComellasMPazSPovedaJLMeleticheDMPolancoCTreatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literaturePatient Prefer Adherence201481653166425525341
   PubMed Web of Science ®Google Scholar
• HowardJTrevickSYoungerDEpidemiology of multiple sclerosisNeurol Clin201634491993927720001
   PubMed Web of Science ®Google Scholar
• ZhangTTremlettHLeungSExamining the effects of comorbidities on disease-modifying therapy use in multiple sclerosisNeurology201686141287129526944268
   PubMed Web of Science ®Google Scholar
• HigueraLCarlinCSAndersonSAdherence to disease-modifying therapies for multiple sclerosisJ Manag Care Spec Pharm201622121394140127882830
   PubMed Web of Science ®Google Scholar
• ManteuffelMWilliamsSChenWVerbruggeRRPittmanDGSteinkellnerAInfluence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelinesJ Womens Health (Larchmt)201423211211924206025
   PubMed Web of Science ®Google Scholar
• UtzKSHoogJWentrupAPatient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysisTher Adv Neurol Disord20147626327525371708
   PubMed Web of Science ®Google Scholar
• HaaseRKullmannJSZiemssenTTherapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS surveyTher Adv Neurol Disord20169425026327366231
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSAdeleinePEarly clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic processBrain2003126Pt 477078212615637
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGBassBRiceGPThe natural history of multiple sclerosis: a geographically based study – 2: predictive value of the early clinical courseBrain1989112Pt 6141914282597989
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGRiceGPNoseworthyJHCarriereWBaskervilleJEbersGCThe natural history of multiple sclerosis: a geographically based study – 3: multivariate analysis of predictive factors and models of outcomeBrain1991114Pt 2104510562043940
   PubMed Web of Science ®Google Scholar
• ErikssonMAndersenORunmarkerBLong-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosisMult Scler20039326027412814173
   PubMed Web of Science ®Google Scholar
• TremlettHYousefiMDevonshireVRieckmannPZhaoYImpact of multiple sclerosis relapses on progression diminishes with timeNeurology200973201616162319890070
   PubMed Web of Science ®Google Scholar
• KeXNavaratnamPSasaneRDeterminants of high cost in multiple sclerosis patients: a claims and chart review studyCurr Med Res Opin20163291589159727207562
   PubMed Web of Science ®Google Scholar
• LuEWangBWGuimondCSafety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilanceExpert Rev Neurother201313325126123448215
   PubMed Web of Science ®Google Scholar
• TarrantsMOleen-BurkeyMCastelli-HaleyJLageMJThe impact of comorbid depression on adherence to therapy for multiple sclerosisMult Scler Int20112011
   Google Scholar
• GajofattoABenedettiMDTreatment strategies for multiple sclerosis: when to start, when to change, when to stop?World J Clin Cases20153754555526244148
   PubMed Web of Science ®Google Scholar